EAT/mcl-1 showed increased expression during the differentiation of a multipotent human embryonic carcinoma cell line, NCR-G3, and of myeloblastic cells "ML-1," and has sequence similarity to Bcl-2. In this present study, we determined whether the apoptotic cell death induced by chemotherapeutic agents could be inhibited by EAT/mcl-1, as has been found with Bcl-2. Cells transfected with EAT/mcl-1 showed higher resistance to cis-diammine dichloroplatinum (II) (CDDP) and carboplatin compared with the parental line (10) 
We previously established a multipotent human embryonic carcinoma (EC) cell line, NCR-G3, to serve as a model system of early human embryogenesis.
1) NCR-G3, which is derived from a testicular EC, possesses pluripotency in differentiation, and is capable of differentiation to trophectoderm cells upon exposure to retinoic acid (RA) or heat shock. 2, 3) These differentiated cells produce human chorionic gonadotropin, a trophectoderm-specific hormone. 1) We employed this system to search for molecules essential for EC cell differentiation. EAT/mcl-1 gene was found to be one such gene; it is up-regulated during the early stage of EC cell differentiation.
3) EAT/mcl-1 was originally identified as a gene which is induced by 12-Otetradecanoylphorbol-13-acetate (TPA) in myeloid leukemic cells. 4) In both cell types, gene expression is increased at the early stages of differentiation upon exposure to inducers.
Since its discovery, EAT/mcl-1 has attracted much interest from various researchers because of its sequence similarity to bcl-2. This group of genes differs from many oncogenes in that it can promote cell survival or inhibit apoptosis without promoting cell proliferation. 5) The ability of Bcl-2 to inhibit apoptosis has been observed in many different cell types, as well as under a variety of conditions, including incubation of sensitive cells with glucocorticoids, removal of required growth factors, or exposure to cytotoxic drugs, γ-radiation or apoptosisinducing gene products such as c-Myc. [6] [7] [8] Several other proteins with sequence similarity to Bcl-2 can also influence cell survival. Bcl-xL was isolated by low stringency hybridization using bcl-2 gene as a probe; Bcl-xL is even more efficacious than Bcl-2 in promoting cell survival under certain apoptosis-inducing conditions. 9) Another family member, Bax, was discovered as a gene product that can heterodimerize with Bcl-2 10) ; the heterodimer appears to protect cells, whereas Bax homodimers cause accelerated apoptosis.
11) Related proteins have been identified in other species, all of which have sequence similarity to the carboxyl region of Bcl-2. The Ced-9 protein of Caenorhabditis elegans prevents programmed cell death during development of this nematode.
12) The Epstein-Barr virus protein BHRF1 can also enhance cell viability. 13, 14) Considering the sequence similarity between EAT/mcl-1 and this Bcl-2 family, it is speculated that EAT/mcl-1 might also influence cell viability. A previous study has shown that apoptosis, induced by c-myc overexpression in Chinese Hamster Ovary (CHO) cell line, was delayed by EAT/mcl-1. 15) Apoptosis induced by etoposide was also reported to be inhibited by EAT/mcl-1 in FDP-C1, murine myeloid progenitor cells. 16) However, little is known about the mechanism by which EAT/mcl-1 contributes to apoptosis. Based on the studies so far reported, several apoptotic pathways have been postulated. 17) Although apoptosis and its inhibition by Bcl-2 have been well documented, [18] [19] [20] [21] [22] similar mechanisms involving EAT/mcl-1 have not been fully elucidated. In this study, we examined whether EAT/mcl-1 overexpression could affect apoptosis induced by chemotherapeutic agents such as cis-diammine dichloroplatinum (II) (CDDP), alkylating agents, antibiotics and topoisomerase inhibitors in (10)1 mouse fibroblast cell line. 23) 
MATERIALS AND METHODS
Cell line and culture Mouse p53-deficient (10)1 fibroblast cell line 23) was grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and incubated at 37°C in a humidified atmosphere of 5% CO 2 and 95% air. Plasmids A cDNA clone containing the entire EAT/mcl-1 coding region was excised with PstI and ApaI from the Bluescript SK(−) vector and blunted. After addition of PstI linker and digestion with PstI, the 2.4-kb fragment obtained was inserted into the PstI site of the pSRα vector. This places EAT/mcl-1 under the SRα promoter. The plasmid pSRα-neo was constructed by cloning the neomycin resistance gene-containing fragment into EcoRI/ HindIII-cut pBR322-SRα. DNA transfection and amplification Cells were transfected by the Lipofectin method (Gibco BRL, Gaithersburg, MD) according to the instructions of the manufacturer. (10)1 cells were plated at a density of 2 ×10 5 cells/ 60 mm dish and grown overnight. Five micrograms of pSRα-neo with or without 0.5 µg of pSRα-EAT/mcl-1 and 10 µg of Lipofectin reagents were added to cells and incubation was continued for 48 h. Cells were grown at a concentration of 600 µg/ml of G418 for approximately 2 weeks. Immunoblotting assay Immunoblot analysis for EAT/ mcl-1 protein was carried out as previously described. 24) Preblocked blots were reacted with rabbit polyclonal antibody against human EAT/mcl-1 (Pharmingen, San Diego, CA) at a 1:2000 dilution in Tris-buffered saline (pH 7.6) with 0.05% Tween 20 (TBS-T) at room temperature for 1 h and then incubated with a 1:2000 dilution of peroxidase-conjugated swine anti-rabbit IgG antibody (Zymed, San Francisco, CA) in TBS-T for 1 h. For immunocytochemistry, we generated a monoclonal antibody, 3A2. The 3A2 monoclonal antibody specifically reacts with human EAT/mcl-1. Immunoblots were developed by using the ECL western blotting detection system (Amersham International, Amersham, UK). Prestained molecular weight markers ("Rainbow" proteins) were obtained from Amersham. DNA fragmentation in (10)1 cells (10)1 cells (5×10 6 cells) were harvested and suspended in 200 µl of DNA extraction buffer (10 mM Tris-HCl [pH 7.4], 10 mM EDTA, 0.5% Triton X-100, 0.4 mg/ml RNase A). After incubation at 37°C for 1 h, a 2-µl aliquot of 20 mg/ml proteinase K was added and the mixture was further incubated for an additional hour. Then the sample was analyzed by electrophoresis in 2% agarose gels followed by ethidium bromide staining. The stained gels were photographed under a UV illuminator. RNA blot analysis RNA was prepared by a standard method. 25) Twenty micrograms of total cellular RNA was denatured with glyoxal, then electrophoresed on a 1.0% agarose gel and blotted onto GeneScreen Plus membranes (NEN Research Products, Boston, MA). The membranes were hybridized with cDNA inserts labeled with [α-
32 P]-dCTP by the random-primer method at 65°C for 14-16 h in a buffer containing 5× SSPE (1× SSPE is 0.18 mol of NaCl, 10 mmol of NaH 2 PO 4 /Na 2 HPO 4 [pH 7.4], and 1 mmol of EDTA), 5× Denhardt's (1× Denhardt's is 0.02% Ficoll, 0.02% polyvinylpyrrolidone, and 0.02% bovine serum albumin), 1% sodium dodecyl sulfate (SDS), and 10 mg/ml poly(A). The blots were washed with 2× SSC (1× SSC is 0.15 mol of NaCl, 50 mmol of NaH 2 PO 4 , and 5 mmol of EDTA), then with 1× SSC containing 1% SDS at room temperature and 65°C. Final washings were with 0.1× SSC containing 0.1% SDS at 65°C. A 2.4-kb full length cDNA designated as EAT/mcl-1 probe was used as a probe.
RESULTS
Chemotherapy is widely used in cancer treatment and many agents are known to induce apoptosis through p53-dependent pathways. [26] [27] [28] Resistance to chemotherapeutic agents has been reported to be acquired by functional mutations of p53 in tumors. 29, 30) Bcl-2 in certain ovarian cell lines expressing mutant p53 was found to further enhance the levels of resistance to CDDP, one of the most commonly used agents in cancer treatment. 31) To determine the role of EAT/mcl-1 gene in resistance to chemotherapeutic agent-induced cell death via p53-independent pathway(s), we transfected EAT/mcl-1 into (10)1 cells, which do not express p53. 23) Generation of (10)1 cells expressing EAT/mcl-1 Cells were transfected with pSRα-EAT/mcl-1 in addition to pSRα-neo (denoted as EAT/n). The gene was expressed in 10 of 12 G418-resistant clonal cell populations as assessed by RNA blot hybridization to an EAT/mcl-1 cDNA probe. Three cell populations expressing EAT/mcl-1 mRNA and protein at different levels ( Fig. 1) were chosen for further analysis. Two clonal populations of control G418-resistant cells transfected with pSRα-neo were also chosen.
(10)1 cells and neo/n had no detectable EAT/mcl-1 expression at the mRNA level (Fig. 1A) . Each EAT/n clonal population expressed the EAT/mcl-1 gene at different levels; EAT/9 expresses the highest level of EAT/mcl-1 and EAT/7 the lowest, relative to (10)1 rRNA accumulation. Similarly, as evaluated by immunoblot analysis, EAT-transfected cells produced various levels of EAT/ mcl-1 (Fig. 1B) . The level of EAT/mcl-1 protein was proportional to the transcriptional level found by RNA blot analysis. The exogenously transfected EAT/mcl-1 protein is localized in the cytoplasm, suggesting that exogenous EAT/mcl-1 may also be localized in the same site (Fig.  2) . There was no remarkable morphological difference between the parental cell line and transfected clones as observed by phase contrast microscopy. Apoptotic cell death was induced by CDDP in a timedependent and concentration-dependent manner To investigate the response of (10)1 to chemotherapeutic agents, we first incubated (10)1 with several concentrations of CDDP and estimated the cell viability at several time points. Cell death of (10)1 was induced by CDDP in a time-dependent manner, and also in a concentrationdependent manner. As the concentration of the drugs was increased, the cell started to die at an early time-point after treatment. The appearance of dying cells was compatible with the specific features of apoptosis (Fig. 3) . The fragmentation of genomic DNA into oligo-nucleosomal-sized units was also detected (Fig. 4) .
Altered resistance of transfected cells to chemotherapeutic agents (10)1, neo/n, and EAT/n clonal populations were tested for relative viability in the presence of several chemotherapeutic agents including CDDP, carboplatin, methotrexate (MTX), etoposide (VEP), mitomycin (MMC), adriamycin (ADM), cyclophosphamide (CPA) and dexamethasone (DEX). EAT/9 and EAT/14 cells showed significant resistance to the toxic effects of CDDP compared with neo/n cells, while EAT/7 cells did not show significant resistance (Fig. 5A) . The difference between control cells and EAT/n cells was most distinct with CDDP and carboplatin (Fig. 5B) . The cell death of transfected EAT/9 and EAT/14 cells was delayed approximately 48 to 72 h compared with that of neo/n cells. In contrast to CDDP and carboplatin, the sensitivity of EAT/ n cells upon exposure to MTX and VEP was similar to that of 10 (1) and 10(1)/neo cells; resistance to apoptosis was not detected with these agents (Fig. 5B) . Similarly, Fig. 3 . EAT/mcl-1 confers CDDP resistance in (10)1 cells, which are p53-deficient. EAT/9 (B and D) cells showed increased resistance to apoptosis induced by CDDP as compared to neo/6 (A and C) control cells. Cells were exposed to 5 µg/ml (upper column, A and B) and 1.5 µg/ml (C, D and E) of CDDP for 24 h. The low cell number of neo/6 as compared to EAT/9 may be due in part to the fact that neo/6 cells treated with CDDP became round in shape and detached from the culture dish. EAT/14 (E) showed similar morphology to EAT/9.
EAT/n cells did not exhibit resistance to treatment with MMC, ADM, CPA and DEX (data not shown).
While expression of endogenous EAT/mcl-1 was not detected in (10)1 and (10)1/neo cells, the levels of EAT/ mcl-1 transcripts varied in transfected (10)1/EAT cell lines (Fig. 1) . Despite this variation, protection (in terms of DNA fragmentation and cell viability) was apparent in EAT/9 and EAT/14 cells. EAT/7 cells without expression of transfected EAT/mcl-1 were indistinguishable from mock-transfected cells. The lack of an expression leveldependent relationship between EAT/mcl-1 transcripts and the ability to delay the onset of apoptosis suggests that these transfectants contained levels of EAT/mcl-1 above the threshold for protection from apoptosis, as previously reported. 15) Since a survival role for EAT/mcl-1 in the regulation of apoptosis has been postulated, 4, 15) overexpression of EAT/ mcl-1 in (10)1 cells may have increased the ability of those cells to form colonies. If so, EAT/n cells would exhibit increased plating efficiency in comparison with neo/n and (10)1 controls. An association between plating efficiency in the absence of these agents and EAT/mcl-1 expression was not observed (data not shown). Furthermore, the growth rate of cells expressing EAT/mcl-1 was not significantly different from that of the control cells, nor did G418 exposure affect the growth of G418-resistant cells.
A major concern is whether the resistance to CDDPinduced apoptosis as conferred by EAT/mcl-1 allowed the Fig. 4 . DNA fragmentation of apoptotic cells. Cells were treated with 1.5 µg/ml and 5 µg/ml of CDDP for 72 h. After treatment, genomic DNA was isolated and electrophoresed in 2% agarose gel. A distinct nucleosomal ladder of 200 bp was observed in neo/6 control cells and (10)1 parental cells. Genomic DNA from EAT/9 showed slight DNA fragmentation, although the fragmentation was apparently less than that of neo/ 6 cells. As a size marker, a 100 bp ladder is shown in the left lane. EAT/14, EAT/9, EAT/7, neo/21, neo/6. B. The relative survival of cells transfected with neomycin or EAT/mcl-1. Each cell line was exposed to 1.5 µg/ml of CDDP for 3 days, 90 µg/ml of carboplatin for 2 days, 300 µg/ ml of MTX for 2 days and 100 µg/ml of VEP for 1 day. neo/6, EAT/9, EAT/14.
cells to survive and then regrow, or whether cell death was merely delayed. We examined the viability of CDDPtreated (10)1 cells at several time points (Fig. 5A) . When (10)1 cells were treated with CDDP, EAT/9 and EAT/14 clones were more resistant than the controls. The survival fractions of drug-treated EAT/9 and EAT/14 clones were always higher than those of (10)1 or neo/n, but cell death was apparent at later time points.
DISCUSSION
Does EAT/mcl-1 modulate apoptosis via a p53-independent pathway? Considering the sequence similarity between EAT/mcl-1 and Bcl-2, 3, 32) and the fact that other family members have been reported to influence cell viability, we speculated that EAT/mcl-1 might influence apoptotic pathways and contribute to differentiation through modulation of cell viability. The present studies show that EAT/mcl-1 delayed cell death induced by CDDP and carboplatin in this system. Since drug resistance can be partly attributed to decreased cellular susceptibility to apoptosis, [33] [34] [35] [36] [37] [38] these data, therefore, support the idea that EAT/mcl-1 contributes to cell survival.
Since (10)1 cells used in this study lack the p53 protein, apoptotic events occur independently of p53. p53 is reported to be involved in the activation of apoptosis, but p53-independent apoptotic pathways also exist. 39, 40) Although p53 has been shown to induce cell cycle arrest and gene expression (p21/waf-1/cdi-1), the mechanism underlying the p53-independent apoptotic pathway involving EAT/mcl-1 remains unclear.
The inhibition of apoptosis by EAT/mcl-1 may be directly correlated with the mechanism of CDDP-induced cell death. 37, 41, 42) The inhibition of DNA repair by adduction of CDDP to DNA is probably the major mechanism contributing to apoptosis. Following such DNA damage by CDDP, c-abl is involved and then the JNK (SAPK) pathway is activated. [43] [44] [45] Since EAT/mcl-1 inhibits release of cytochrome c from mitochondria, EAT/mcl-1 may function downstream of c-abl/JNK (SAPK) and therefore inhibit apoptosis induced by CDDP or carboplatin. The other possibility is that EAT/mcl-1 affects the accumulation of CDDP, and thus changes the chemosensitivity. 46) EAT/mcl-1 may induce or interact with an efflux pump for these drugs.
Relatively weak modification of apoptosis by EAT/mcl-1 may be attributed to lack of p53 Since the ratio of bcl-2:bax plays an important role in the induction of apoptosis, 17) the possibility of transactivation of other bcl-2 gene family members by p53 must be taken into consideration. Since (10)1 cells do not possess wild-type p53, the ratio of molecules which determine the induction of apoptosis may be disturbed. This may lead to the slight modification of apoptotic cell death observed with EAT/mcl-1. If this is the case, we cannot completely eliminate the possibility that failure of EAT/mcl-1 to inhibit apoptosis induced by CPA, ADM and VEP is limited in the cells used in this study. Inhibition of apoptosis by bcl-2 depends on the cells used. In p53-deficient lymphoma cells, bcl-2 significantly inhibits apoptosis by VEP, CDDP and MMC. 47) In contrast, bcl-2 does not prevent apoptosis by CDDP, VEP and MTX in lung small cell carcinoma cells. 48, 49) Clinical implications of EAT/mcl-1 Our data provide further evidence of the ability of this protein to confer a survival advantage upon tumor cells. 43, 50) We may consider a scenario in vivo in which a mixed population of EAT/mcl-1 positive and negative tumor cells are differentially susceptible to chemotherapy, and in which the more susceptible EAT/mcl-1 negative tumor cells are more rapidly cleared out, resulting in an initial response to chemotherapy, while a resistant EAT/mcl-1 positive cell population develops which may be associated with subsequent relapse.
